This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Apricus Biosciences Announces Poster Presentations On Progress Of PrevOnco(TM) In Combination With NexACT(R) Technology At The American Association For Cancer Research 2011 Annual Meeting

SAN DIEGO, March 22, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will present two posters at the American Association for Cancer Research ("AACR") 102 nd Annual Meeting to be held April 2-6, 2011 in Orlando, Florida.

The presentations will include one poster discussing how the Company's NexACT ® technology, involving a small molecule permeation enhancer called Dodecyl 2-(N,N dimethylamino) propionate ("DDAIP"), improves the pharmacokinetic profile of PrevOnco , Apricus Bio's proprietary drug for human hepatocellular carcinoma ("HCC") or liver cancer, in different species in mice, beagle dogs and cynomolgus monkeys. The second poster discusses the anti-tumor activity of PrevOnco in in vitro and in vivo human tumor models using a combination therapy of PrevOnco and Doxorubicin that resulted in a better efficacy profile with enhanced survival rate in a liver cancer model.

PrevOnco Posters

Title: DDAIP improves the pharmacokinetic profile of PrevOnco ® in different species: Comparison of DDAIP, CMC and PEG-300/400 formulations in mice, beagle dogs and cynomolgus monkeys. 

Abstract Number:  1297
April 4, 2011:  8:00 am to 12:00 pm ET
Session Title:  Pharmacokinetics and Metabolism
Session Category:  Clinical Research 5
Poster Section:  13
Board Number:  9

Title: PrevOnco exhibits anti-tumor activity in in vitro and in vivo human tumor models: Combination therapy (PrevOnco /Doxorubicin) demonstrates a better efficacy profile with enhanced survival rate in a liver cancer model.

Abstract Number:  2535
April 4, 2011: 1:00 pm to 5:00 pm ET
Session Title:  Chemotherapeutic Agents
Session Category:  Experimental and Molecular Therapeutics 15
Poster Section:  26
Board Number  20

About PrevOnco

PrevOnco is Apricus Bio's proprietary treatment for HCC or liver cancer. The product incorporates lansoprazole, a commonly marketed anti-ulcer compound which has shown strong anti-cancer activity in mice bearing human liver tumors. The U.S. Food & Drug Administration ("FDA") granted PrevOnco Orphan Drug status in August 2008. The Company is currently in discussions with the FDA regarding a Special Protocol Assessment ("SPA") Phase III protocol which was submitted in November 2011, and expects to have a final protocol agreed upon within eight to 12 months. 

About Apricus Biosciences, Inc.

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT ® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros ®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on sexual dysfunction, oncology, dermatology, autoimmune, pain, anti-infectives, diabetes and cosmeceuticals among others.

For further information on Apricus Bio, visit http://www.apricusbio.com and for information on its subsidiaries please visit www.nexmedusa.com or www.bio-quant.com . You can also find out more about the company by visiting http://twitter.com/apricusbio , http://facebook.com/apricusbio .

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, the FDA and other countries' regulatory approval of PrevOnco and other of its products and product candidates, its ability to commercialize such products and to enter into license agreements with potential pharmaceutical partners and obtain upfront and milestone payments as well as royalties and to achieve other of its financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

CONTACT: Apricus Biosciences, Inc.
         Edward Cox, V.P.
         Investor Relations & Corporate Development
         Apricus Bio, Inc.
         (858) 848-4249
         ecox@apricusbio.com
         
         Apricus Bio Investor Relations
         Paula Schwartz
         Rx Communications Group, LLC
         (917) 322-2216
         pschwartz@rxir.com

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,678.98 -97.14 -0.55%
S&P 500 2,057.72 -10.17 -0.49%
NASDAQ 4,862.8560 -38.0290 -0.78%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs